Application of Tumor Markers in Patients with Urachal Carcinoma

• Main Authors: KE Chunjin, HU Zhiquan, YUE Daoyuan, SHEN Yuanqing, GAN Jiahua, TIAN Jihua, LI Song, LI Le, YANG Chunguang
• Format: Article
• Language: zho
• Published: Magazine House of Cancer Research on Prevention and Treatment 2020-09-01
• Series: Zhongliu Fangzhi Yanjiu
• Subjects: urachal carcinoma; adenocarcinoma; tumor markers; diagnosis
• Online Access: http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0161.htm
• ISSN: 1000-8578; 1000-8578

Objective To analyze the expression of CEA, CA199 and CA724 in patients with urachal carcinoma, and to explore their correlation with disease diagnosis, staging, progression and treatment response. Methods Twelve urachal carcinoma patients with related tumor markers were selected as the research object and further divided into distant metastasis group (n=4) and non-metastasis group (n=8). We selected 40 patients with urothelial carcinoma of the bladder and 40 healthy people as the control groups. SPSS 23.0 and MedCalc 19 were used for data analysis. Results Twelve patients with urachal carcinoma were all adenocarcinomas. The expression of CEA in the urachal carcinoma group was significantly higher than that in urothelial carcinoma group and healthy control group (P=0.01). The positive rate of CA724 in the distant metastasis group was significantly higher than that in the non-metastasis group (75% vs. 0, P=0.018). In single test, CEA diagnosed urachal carcinoma with the highest AUC of 0.750 and 95%CI of 0.584 to 0.916. The AUC detected by the combination of both CEA and CA724 or three tumor markers were all larger than the AUC detected by single test, but without statistical significance (0.817 vs. 0.805, P=0.8509). Conclusion The expression of CEA in patients with urachal carcinoma is significantly increased. CA724 can be used as a predictor of distant metastasis of urachal carcinoma, and the combination detection of CA724 and CEA can provide an effective reference for the clinical diagnosis of urachal cancer.